PGMiner: Complete proteogenomics workflow; from data acquisition to result visualization

De Novo Sequencing of Peptides from Tandem Mass Spectra and Applications in Proteogenomics

The changes in protein expression are hallmarks of development and disease. Protein expression can be established qualitatively and quantitatively using mass spectrometry (MS). Samples are prepared, proteins extracted and then analyzed using MS and MS/MS. The resulting spectra need to be processed computationally to assign peptide spectrum match. Database searches employ sequence databases or spectral libraries for matching possible peptides with the measured spectra. This route is well established but fails when peptides are not found in sequence repositories. In this case, de novo sequencing of MS/MS spectra can be employed. Many computational algorithms that establish the peptide sequence from MS/MS spectrum alone are available. While de novo sequencing assigns a sequence to an MS/MS spectrum, this assignment can be used in further processes for genome annotation. For example, novel exons can be assigned, known exons can be extended, and splice sites can be validated at the protein level. We compiled an extensive list of such algorithms, grouped them, and discussed the selected approaches. We also provide a roadmap of how de novo sequencing can enter mainstream proteogenomic analysis. In the future, de novo predictions can be added to sample-specific protein databases, including RNA-seq translations. These enriched databases can then be used for proteogenomics studies with existing pipelines.

Comprehensive Peptide Mapping Is Crucial for Proteogenomics and Proteomics

Proteogenomics enables the confirmation and refinement of gene models, the detection of new ones, and the proposition of alternative transcripts using support at the protein level. Such evidence is usually generated using mass spectrometry and subsequent result mapping to various sequence databases. This workflow entails several problems: (1) To speed up the analysis, only a small set of expected proteins is searched; (2) database search tools generally do not provide mapping to the genome; and (3) upon new releases of the sequence databases, expensive rerunning of all results would need to be performed. Therefore, fast and accurate peptide mapping is needed as part of proteogenomic pipelines. Unfortunately, some available tools have technical shortcomings. Thus, a set of test cases was developed to allow tool developers to test their implementations comprehensively. The need for comprehensive testing is exemplified by PGx and PGM, two published tools that could only solve a subset of test cases. Lelantos passed all test cases. A set of comprehensive test cases has been developed to overcome these issues. Many unpublished peptide mapping tools are part of proteogenomic workflows, and such tools would also benefit from comprehensive testing. Finally, peptide mapping may also be crucial for proteomics because sequence databases change over time. In response, peptide remapping should be performed to ensure that peptides identifying a protein are proteotypic in a larger sequence context.

Peptidomics and proteogenomics: background, challenges and future needs

INTRODUCTION

With available genomic data and related information, it is becoming possible to better highlight mutations or genomic alterations associated with a particular disease or disorder. The advent of high-throughput sequencing technologies has greatly advanced diagnostics, prognostics, and drug development.

AREAS COVERED

Peptidomics and proteogenomics are the two post-genomic technologies that enable the simultaneous study of peptides and proteins/transcripts/genes. Both technologies add a remarkably large amount of data to the pool of information on various peptides associated with gene mutations or genome remodeling. Literature search was performed in the PubMed database and is up to date.

EXPERT OPINION

This article lists various techniques used for peptidomic and proteogenomic analyses. It also explains various bioinformatics workflows developed to understand differentially expressed peptides/proteins and their role in disease pathogenesis. Their role in deciphering disease pathways, cancer research, and biomarker discovery using biofluids is highlighted. Finally, the challenges and future requirements to overcome the current limitations for their effective clinical use are also discussed.

Methods for Proteogenomics Data Analysis, Challenges, and Scalability Bottlenecks: A Survey

Big Data Proteogenomics lies at the intersection of high-throughput Mass Spectrometry (MS) based proteomics and Next Generation Sequencing based genomics. The combined and integrated analysis of these two high-throughput technologies can help discover novel proteins using genomic, and transcriptomic data. Due to the biological significance of integrated analysis, the recent past has seen an influx of proteogenomic tools that perform various tasks, including mapping proteins to the genomic data, searching experimental MS spectra against a six-frame translation genome database, and automating the process of annotating genome sequences. To date, most of such tools have not focused on scalability issues that are inherent in proteogenomic data analysis where the size of the database is much larger than a typical protein database. These state-of-the-art tools can take more than half a month to process a small-scale dataset of one million spectra against a genome of 3 GB. In this article, we provide an up-to-date review of tools that can analyze proteogenomic datasets, providing a critical analysis of the techniques' relative merits and potential pitfalls. We also point out potential bottlenecks and recommendations that can be incorporated in the future design of these workflows to ensure scalability with the increasing size of proteogenomic data. Lastly, we make a case of how high-performance computing (HPC) solutions may be the best bet to ensure the scalability of future big data proteogenomic data analysis.